Search our Database of Scientific Publications and Authors

I’m looking for a

    1440 results match your criteria Psoriasis Pustular

    1 OF 29

    Abrupt generalized pustules in patients with rheumatoid arthritis and interstitial lung disease.
    J Dermatol 2017 Nov 23. Epub 2017 Nov 23.
    Peking University China-Japan Friendship School of Clinical Medicine, Beijing, China.
    We report a case of a 30-year-old Chinese woman with rheumatoid arthritis and interstitial lung disease who abruptly developed generalized pustules and a high fever for 10 days. She had been taking oral prednisone, iguratimod and total glucosides of peony regularly for 5 months prior. In addition, she had taken metronidazole for 3 days 20 days prior which she had used before with no adverse reaction. Read More

    The Efficacy of Biologic Therapy for the Management of Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review.
    Dermatol Ther (Heidelb) 2017 Dec 15;7(4):425-446. Epub 2017 Nov 15.
    Department of Dermatology, University of California San Francisco, San Francisco, USA.
    Introduction: Palmoplantar psoriasis (PP) and palmoplantar pustulosis (PPP) are diseases affecting the hands and/or feet that can cause marked physical discomfort and functional disability. The tumor necrosis factor-alpha antagonists adalimumab, etanercept, and infliximab, the interleukin (IL)-17A inhibitors ixekizumab and secukinumab, and the IL-23 or IL-12/IL-23 inhibitors guselkumab and ustekinumab have been well studied for the treatment of moderate to severe plaque psoriasis. Less is known about the efficacy and safety of these agents for the treatment of PP (hyperkeratotic and pustular forms) and PPP. Read More

    Paradoxical Reactions: Anti-Tumor Necrosis Factor Alpha Agents, Ustekinumab, Secukinumab, Ixekizumab, and Others.
    Curr Probl Dermatol 2018 7;53:49-63. Epub 2017 Nov 7.
    Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
    Paradoxical reactions during treatment with a biologic agent can be defined as the appearance or exacerbation of a pathological condition that usually responds to this class of drug while treating a patient for another condition, which usually remains under control (even though there may be a change in morphology or phenotype). Paradoxical reactions were initially described as isolated case reports or case series in patients treated with anti-tumor necrosis factor (TNF) α agents, first in inflammatory rheumatic diseases, later in psoriasis and inflammatory bowel disease. Paradoxical reactions have subsequently been reported with other biological drugs or classes (e. Read More

    Epidemiological survey from 2009 to 2012 of psoriatic patients in Japanese Society for Psoriasis Research.
    J Dermatol 2017 Nov 8. Epub 2017 Nov 8.
    Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan.
    Since 1982, the Japanese Society for Psoriasis Research has conducted annual epidemiological surveys of patients with psoriasis. Kawada et al. have reported data for 1982-2001 and Takahashi et al. Read More

    Efficacy and safety of acitretin monotherapy in children with pustular psoriasis: results from 15 cases and a literature review.
    J Dermatolog Treat 2017 Nov 9:1-11. Epub 2017 Nov 9.
    c Institute of Dermatology , Guangzhou Medical University , Guangzhou , P.R. China.
    Background: There is a few evidence-based information regarding the efficacy and safety of acitretin treatment in children with pustular psoriasis (PP).

    Objective: This study aimed to provide an additional evidence for this field.

    Methods: A retrospective study was undertaken for 15 children with PP who received acitretin in doses of 0. Read More

    A mysterious abdominal pain during active psoriasis.
    Intern Emerg Med 2017 Oct 30. Epub 2017 Oct 30.
    Dipartimento di Fisiopatologia Medico-Chirurgica E dei Trapianti, Università degli Studi di Milano, Unità Operativa di Dermatologia, IRCCS Fondazione Ca' Granda, Ospedale maggiore Policlinico, via Pace 9, 24125, Milan, Italy.

    The spectrum of manifestations in DSP (desmoplakin) SR6 domain mutations: immunophenotyping and response to ustekinumab.
    J Am Acad Dermatol 2017 Oct 21. Epub 2017 Oct 21.
    Department of Dermatology, Mount Sinai School of Medicine, New York, NY.
    Background: The immune abnormalities underlying the ichthyoses are poorly understood.

    Objective: To determine the immunophenotype of an ichthyosis resulting from mutations in the spectrin repeat 6 (SR6) domain of DSP, the gene encoding desmoplakin, and to target therapy based on the molecular pathogenesis.

    Methods: Immunophenotyping was performed using the blood and skin of a girl with SR6 region DSP mutations causing erythroderma/ichthyosis and cardiomyopathy. Read More

    Epidemiological survey of patients with psoriasis in Matsumoto city, Nagano Prefecture, Japan.
    J Dermatol 2017 Oct 19. Epub 2017 Oct 19.
    Department of Dermatology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.
    A local epidemiological survey of psoriasis was conducted from 19 February to 30 June 2016 in Matsumoto city, Nagano Prefecture, Japan. Patients were predominantly male (268 cases, 71.5% males vs 107 cases, 28. Read More

    Dynamics of Plasma Cytokines in a Patient with Deficiency of Interleukin-36 Receptor Antagonist Successfully Treated with Anakinra.
    Br J Dermatol 2017 Oct 13. Epub 2017 Oct 13.
    Departments of Dermatology, Hospital Clínic de Barcelona, IDIBAPS, Barcelona, Spain.
    Generalized pustular psoriasis (GPP) is an autoinflammatory disease characterized by abrupt-onset episodes of erythematous skin plaques with countless pustules, fever, marked neutrophilia and increased acute phase reactants (APR).(1) Loss-of-function mutations in the IL36RN gene, encoding for interleukin (IL)-36 receptor antagonist (IL-36Ra), have been described in a significant proportion of GPP patients.(2,3) Previous studies have shown in vitro and ex vivo enhanced production of pro-inflammatory cytokines (IL-1, IL-6 and IL-8) and successful outcomes with anti-IL-1 drugs in patients carrying IL36RN mutations. Read More

    Generalized pustular psoriasis triggered by Zika virus infection.
    Clin Exp Dermatol 2017 Oct 13. Epub 2017 Oct 13.
    Public Health and Infection Research Group, Faculty of Health Sciences, Universidad Tecnológica de Pereira, Pereira, Colombia.
    Zika virus is an emerging arbovirus, which is expanding in epidemic proportions through tropical and subtropical areas of the world. Although Zika is linked to a number of congenital and neurological complications, there is scarce knowledge on the impact of ZIKV infection in human skin. We report the case of a 68-year old woman who presented with generalized pustular psoriasis after a preceding and otherwise uneventful episode of ZIKV infection. Read More

    TNFα and IL-17A are differentially expressed in psoriasis-like vs eczema-like drug reactions to TNFα antagonists.
    J Cutan Pathol 2017 Oct 10. Epub 2017 Oct 10.
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
    Background: Tumor necrosis factor α (TNFα) blocking drugs are in use for a wide range of autoimmune disorders. In up to 5% of patients, this class of drugs produces puzzling cutaneous side effects that are the subject of this investigation, namely psoriasiform and eczema-like skin inflammation. These side effects can occur after any time of treatment and regardless of the underlying disorders. Read More

    Intracorneal pustular drug eruption, a novel cutaneous adverse event in anti-programmed cell death-1 patients that highlights the effect of anti-programmed cell death-1 in neutrophils.
    Melanoma Res 2017 Dec;27(6):641-644
    aDepartment of Dermatology bDepartment of Pathology, Institute for Clinical Pathology and Medical Research, Westmead Hospital cDepartment of Dermatology, Faculty of Medicine, University of Sydney, Sydney, New South Wales, Australia.
    The introduction of anti-programmed cell death-1 (anti-PD1) monoclonal antibodies has revolutionized the treatment of various advanced malignancies. Despite its efficacy, anti-PD1 therapy is accompanied by a variety of cutaneous adverse events. A 79-year-old man developed erythematous scaly plaques and pustules of the forehead, legs and arms after four cycles of nivolumab infusions every 2 weeks. Read More

    Cutaneous Manifestations of Chikungunya Fever: Observations from an Outbreak at a Tertiary Care Hospital in Southeast Rajasthan, India.
    Indian Dermatol Online J 2017 Sep-Oct;8(5):336-342
    Department of Dermatology, Venereology and Leprology, Government Medical College, Kota, Rajasthan, India.
    Background: Chikungunya fever is caused by chikungunya virus which is transmitted by the bite of infected Aedes aegypti and A. albopictus mosquitoes.

    Aims: To study the various mucocutaneous manifestations in suspected cases of chikungunya fever. Read More

    Recurrent impetigo herpetiformis: case report.
    Pan Afr Med J 2017 24;27:219. Epub 2017 Jul 24.
    Faculty of Health Sciences, Egerton University, Njoro, Kenya.
    Impetigo herpetiformis (pustular psoriasis of pregnancy) is a rare dermatosis of pregnancy that typically starts in the 2(nd) half of pregnancy and resolves postpartum. It may recur in subsequent pregnancies. I present a case of 23 year old female gravida 4 para 3 with recurrent impetigo herpetiformis at 26 weeks gestation. Read More

    Highlighting Interleukin-36 Signalling in Plaque Psoriasis and Pustular Psoriasis.
    Acta Derm Venereol 2017 Oct 2. Epub 2017 Oct 2.
    Department of Dermatology, Kyushu University, Maidashi 3-1-1, Higashiku, Fukuoka, 812-8582, Japan.
    Plaque psoriasis and pustular psoriasis are overlapping, but distinct, disorders. The therapeutic response to biologics supports the pivotal role of the tumour necrosis alpha (TNF-α)/ interleukin (IL)-23/IL-17/IL-22 axis in the pathogenesis of these disorders. Recently, functional activation of the IL-36 receptor (IL-36R) was discovered to be another driving force in the pathogenesis of psoriasis. Read More

    The genetic basis for most patients with pustular skin disease remains elusive.
    Br J Dermatol 2017 Aug 5. Epub 2017 Aug 5.
    Institute of Human Genetics, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
    Background: Rare variants in the genes IL36RN, CARD14 and AP1S3 have been identified to cause/ contribute to pustular skin diseases, primarily generalized pustular psoriasis (GPP).

    Objectives: To better understand the disease-relevance of these genes, we screened our cohorts of patients with pustular skin diseases (primarily GPP and palmoplantar pustular psoriasis [PPP]) for coding changes in these three genes. Carriers of single heterozygous IL36RN mutations were screened for a second mutation in IL36RN. Read More

    Eczema in Psoriatico: An Important Differential Diagnosis Between Chronic Allergic Contact Dermatitis and Psoriasis in Palmoplantar Localization.
    Acta Derm Venereol 2017 Aug 30. Epub 2017 Aug 30.
    Department of Dermatology and Venereology, Otto-von-Guericke-University Magdeburg, Leipziger Str. 44, DE-39120 Magdeburg, Germany.
    Differential diagnosis of palmoplantar non-pustular psoriasis and chronic allergic contact dermatitis (ACD) and the combination of these conditions, termed "eczema in psoriatico" (EIP), is difficult, especially in cases of isolated involvement. A blind re-evaluation of 63 archived formalin-fixed palmoplantar samples, previously diagnosed clinically as either psoriasis or chronic ACD, was performed. Samples were allocated to histopathological diagnoses of psoriasis, contact dermatitis or EIP. Read More

    Pustular Palmoplantar Psoriasis Successfully Treated with Nb-UVB Monochromatic Excimer Light: A Case-Report.
    Open Access Maced J Med Sci 2017 Jul 19;5(4):462-466. Epub 2017 Jul 19.
    Universitario di Ruolo, Dipartimento di Scienze Dermatologiche, Università degli Studi di Firenze, Facoltà di Medicina e Chirurgia, Dermatology, Via Vittoria Colonna 11, Rome 00186, Italy.
    Barber's palmoplantar pustulosis (PPP) is a form of localised pustular psoriasis, affecting the palmar and plantar surfaces. It is a chronic disease, with a deep impact on the patients' quality of life. The Authors discuss a case of Baber Psoriasis successfully treated with monochromatic excimer light. Read More

    Acute generalized exanthematous pustulosis and polyarthritis associated with a novel CARD14 mutation.
    Australas J Dermatol 2017 Aug 3. Epub 2017 Aug 3.
    Department of Dermatology, Hospital Clinic, Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
    Acute generalised exanthematous pustulosis (AGEP) is a rare toxicoderma characterised by an acute onset rash, with many sterile pustules on the surface, high fever and increased acute phase reactants. We report the case of a patient who presented to the dermatology department with an AGEP and polyarthritis, in which a novel CARD14 mutation was identified. The pathophysiological mechanism of AGEP remains unclear, although mutations in the IL36RN gene have been identified in a small subset of AGEP patients. Read More

    Skin Manifestations of Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, and Spondyloarthritides.
    Clin Rev Allergy Immunol 2017 Dec;53(3):371-393
    Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
    Extra-articular manifestations of rheumatoid arthritis, juvenile idiopathic arthritis, and various spondyloarthritides including psoriatic arthritis, ankylosing spondylitis, reactive arthritis, and inflammatory bowel disease-associated spondyloarthritis often involve the skin and may occur before or after diagnosis of these rheumatic diseases. Cutaneous manifestations encompass a wide range of reactions that may have a notable negative impact not only on the physical but especially on the emotional and psychosocial well-being of these patients. Several cutaneous manifestations have been related to rheumatoid arthritis such as subcutaneous nodules including classical rheumatoid nodules, accelerated rheumatoid nodulosis, and rheumatoid nodulosis; vascular disorders like rheumatoid vasculitis, livedo racemosa, and Raynaud's phenomenon; and neutrophilic and/or granulomatous diseases like pyoderma gangrenosum, Sweet's syndrome, rheumatoid neutrophilic dermatitis, interstitial granulomatous dermatitis with arthritis, as well as palisaded neutrophilic and granulomatous dermatitis. Read More

    Autoinflammatory diseases in dermatology: DITRA and CAMPS.
    Nihon Rinsho Meneki Gakkai Kaishi 2017 ;40(3):169-173
    Department of Dermatology, Fujita Health University School of Medicine.
    Deficiency of interleukin thirty-six receptor antagonist (DITRA) and CARD14 mediated psoriasis (CAMPS) are autoinflammatory diseases in dermatology. The causative genes of DITRA and CMAPS have been identified recently. In this paper, IL36RN and CARD14, the causative gene for DITRA and CAMPS, respectively were explained. Read More

    Psoriasis: a mixed autoimmune and autoinflammatory disease.
    Curr Opin Immunol 2017 Jul 21;49:1-8. Epub 2017 Jul 21.
    Department of Dermatology, University of Michigan, 1910 Taubman Center, 1500 E. Medical Center Drive, Ann Arbor, MI 48109, USA. Electronic address:
    In recent years marked progress has been made in our understanding of the critical biologic and immunologic pathways involved in psoriasis. Genetic studies have demonstrated that susceptibility to psoriasis involves components of both the adaptive and innate immune system and not surprisingly activation of both of these arms of the immune system is found in psoriatic skin. While adaptive immune responses predominate in chronic plaque psoriasis, innate and autoinflammatory responses dominate in pustular forms of psoriasis, with other clinical subtypes extending on a spectrum between plaque and pustular psoriasis. Read More

    Generation and functional characterization of anti-human and anti-mouse IL-36R antagonist monoclonal antibodies.
    MAbs 2017 Oct 20;9(7):1143-1154. Epub 2017 Jul 20.
    a Boehringer Ingelheim Pharmaceuticals Inc. , Ridgefield , CT ., USA.
    Deficiency of interleukin (IL)-36 receptor antagonist (DITRA) syndrome is a rare autosomal recessive disease caused by mutations in IL36RN. IL-36R is a cell surface receptor and a member of the IL1R family that is involved in inflammatory responses triggered in skin and other epithelial tissues. Accumulating evidence suggests that IL-36R signaling may play a role in the pathogenesis of psoriasis. Read More

    UVA1 vs. narrowband UVB phototherapy in the treatment of palmoplantar pustulosis: a pilot randomized controlled study.
    Lasers Med Sci 2017 Nov 11;32(8):1819-1823. Epub 2017 Jul 11.
    Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, People's Republic of China.
    UVA1 phototherapy, a new therapeutic approach, has recently been shown good efficacy in the treatment of palmoplantar pustulosis (PPP). The purpose of this study was to compare the efficacy of UVA1 and narrowband UVB (NB-UVB) therapy in the treatment of PPP. Patients with PPP were randomly assigned to either UVA1 or NB-UVB therapy according to a left-right randomization table. Read More

    Brodalumab: the first anti-IL-17 receptor agent for psoriasis.
    Drugs Today (Barc) 2017 May;53(5):283-297
    Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
    Psoriasis is a chronic immune-mediated inflammatory skin disease in which the alteration of the interleukin-23 (IL-23)/IL-17 cytokine axis appears to be crucial from a pathogenetic perspective. This has been confirmed by the efficacy of monoclonal antibodies blocking IL-17A, such as secukinumab and ixekizumab. Brodalumab is a human anti-IL-17 receptor A (IL-17RA) monoclonal antibody that inhibits the biological activity of IL-17A, IL-17F and other IL-17 isoforms, and has been approved (210 mg s. Read More

    Mutation in IL36RN impairs the processing and regulatory function of the interleukin-36-receptor antagonist and is associated with DITRA syndrome.
    Exp Dermatol 2017 Jun 11. Epub 2017 Jun 11.
    Sorbonne Paris Cité, IMAGINE Institute, Necker Hospital, Enfants-Malades, UMR 1163, Paris-Descartes University, Paris, France.
    The identification of loss-of-function mutations of the IL36RN gene encoding the interleukin-36 receptor antagonist (IL-36Ra) in generalized pustular psoriasis (GPP) emphasized the key role of this pathway in skin innate immunity and systemic inflammation. It has been previously shown in vitro that removal of the N-terminal amino acid IL36Ra (M1) is critical to its biological activity, but the in vivo contribution of this processing remains unknown. We report herein a new homozygous (c4G>T, pV2F) missense IL36RN mutation segregating in a family with three GPP-affected patients. Read More

    Early relapse of psoriasis after stopping brodalumab: a retrospective cohort study in 77 patients.
    J Eur Acad Dermatol Venereol 2017 Sep 8;31(9):1491-1496. Epub 2017 Aug 8.
    Department of Dermatology, Larrey Hospital and Toulouse University, Toulouse, France.
    Background: Biological agents targeting IL-17 are very effective for clearing moderate to severe psoriasis. There is limited information regarding the frequency and pattern of psoriasis relapse upon treatment cessation.

    Objective: To investigate the pattern of psoriasis recurrence in patients who were treated with brodalumab following Amgen's decision to stop the clinical programme in June 2015. Read More

    European consensus statement on phenotypes of pustular psoriasis.
    J Eur Acad Dermatol Venereol 2017 Nov 29;31(11):1792-1799. Epub 2017 Aug 29.
    Division of Genetics and Molecular Medicine, King's College, London, UK.
    Pustular psoriasis (PP) is a group of inflammatory skin conditions characterized by infiltration of neutrophil granulocytes in the epidermis to such an extent that clinically visible sterile pustules develop. Because of clinical co-incidence, PP is currently grouped with psoriasis vulgaris (PV). However, PP and PV are phenotypically different, respond differently to treatments and seem to be distinct on the genetic level. Read More

    Psoriasis in patients with mycosis fungoides: a clinicopathological study of 25 patients.
    J Eur Acad Dermatol Venereol 2017 Nov 16;31(11):1848-1852. Epub 2017 Aug 16.
    Cutaneous Lymphoma Clinic, "Andreas Sygros" Hospital for Skin Diseases, Athens, Greece.
    Background: It has been reported that patients with psoriasis are at increased risk for developing lymphoma including cutaneous T-cell lymphomas (CTCL). However, the comorbidity and the histopathologic correlation of psoriasis and mycosis fungoides (MF) have been less studied.

    Objective: The objective of this study was to investigate the relation between MF and psoriasis. Read More

    Short- and Long-Term Management of an Acute Pustular Psoriasis Flare: A Case Report.
    J Cutan Med Surg 2017 Sep/Oct;21(5):452-456. Epub 2017 May 23.
    2 Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
    Background: Generalised pustular psoriasis (GPP) and acrodermatitis continua of Hallopeau (ACH) are chronic, relapsing variants of pustular psoriasis proven to be remarkably challenging to treat. Due to their uncommon presentation, there are few described cases in literature and scarce evidence for management. Further information is needed to help dermatologists formulate treatment plans for patients presenting with such diseases. Read More

    New Interleukins in Psoriasis and Psoriatic Arthritis Patients: The Possible Roles of Interleukin-33 to Interleukin-38 in Disease Activities and Bone Erosions.
    Dermatology 2017 10;233(1):37-46. Epub 2017 May 10.
    Department of Rheumatology, Linyi People's Hospital, Shandong, China.
    Objectives: New interleukins (ILs), especially members of IL-1 and IL-12 families, have recently been reported to be involved in the development and regulation of autoimmune and inflammatory diseases. In this study, we aimed to explore the impact of these new ILs in psoriasis (Ps) and psoriatic arthritis (PsA).

    Methods: Forty PsA patients, 20 Ps patients, and 20 healthy controls (HCs) were recruited. Read More

    Pediatric psoriasis: Should we be concerned with comorbidity? Cross-sectional study.
    Pediatr Int 2017 Aug 14;59(8):923-928. Epub 2017 Jul 14.
    Department of Dermatology, University Hospital Hassan II, Fez, Morocco.
    Background: Similarly to psoriasis in adults, recent research has linked psoriasis to several comorbidities in children. The aim of this study was therefore to describe comorbidities associated with pediatric psoriasis, to investigate their relationship with psoriasis characteristics and severity, and to perform a review of the literature.

    Methods: A cross-sectional study was performed on a sample of Moroccan children with psoriasis, in 2014-2016. Read More

    A dramatic response to a single dose of infliximab in a patient with prolonged pustular psoriasis derived from inverse psoriasis.
    Dermatol Ther 2017 Jul 17;30(4). Epub 2017 Apr 17.
    Department of Dermatovenereology, West China Hospital of Sichuan University, Chengdu, Sichuan, China.
    We report a case of a 25-year-old Chinese man with an exceptionally prolonged history of pustular psoriasis derived from inverse psoriasis who was unsatisfied with conventional treatment and was successfully treated with a single dose of infliximab without noticeable adverse effects. No recurrence or flaring was observed after 3 months of follow-up. This case illustrates that infliximab may be an effective and safe therapeutic option for patients with refractory pustular psoriasis derived from inverse psoriasis. Read More

    Cutaneous allergic drug reactions: update on pathophysiology, diagnostic procedures and differential diagnosic.
    Cutan Ocul Toxicol 2017 Dec 27;36(4):307-316. Epub 2017 Apr 27.
    a Department of Dermatology and Allergology , RWTH Aachen University , Aachen , Germany.
    Important changes in the understanding and management of drug hypersensitivity reactions during the last years result from the increasing importance of biologics in medical practice, which differ in their spectrum of adverse drug reactions (ADRs) from the classical covalent drugs. With regard to covalent drugs, ampicillin and amoxicillin as well as clavulanic acid play an increasing role among ADRs to betalactam antibiotics. Fluoroquinolones are mainly the cause of anaphylactic and photosensitivity reactions. Read More

    Granulocyte and monocyte apheresis can control juvenile generalized pustular psoriasis with mutation of IL36RN.
    Br J Dermatol 2017 Mar 30. Epub 2017 Mar 30.
    Department of Dermatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
    Patients with deficiency of interleukin-36 receptor antagonist (DITRA), due to mutation of IL36RN, exhibit psoriatic phenotypes, typically generalized pustular psoriasis (GPP). We report a paediatric patient with DITRA, whose cutaneous lesions varied from psoriasis vulgaris in infancy to annular pustular psoriasis with acute exacerbation to GPP at 13 years of age. Conventional systemic treatments for GPP, which include oral retinoids, ciclosporin and methotrexate, are controversial in paediatric cases, because of their adverse effects and uncertain long-term consequences. Read More

    Palmoplantar pustulosis and pustulotic arthro-osteitis treatment with potassium iodide and tetracycline, a novel remedy with an old drug: a review of 25 patients.
    Int J Dermatol 2017 Aug 30;56(8):889-893. Epub 2017 Mar 30.
    Department of Dermatology, Dokkyo Medical University, School of Medicine, Mibu, Tochigi, Japan.
    Background: The use of potassium iodide (KI) to treat palmoplantar pustulosis (PPP) and pustulotic arthro-osteitis (PAO) has not previously been reported. Here, we report the first successful treatment of PPP and PAO with KI.

    Patient And Methods: Among 25 patients with PPP, seven had an associated PAO. Read More

    Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3).
    J Eur Acad Dermatol Venereol 2017 Oct 26;31(10):1686-1692. Epub 2017 Apr 26.
    Dermatologikum Hamburg and SCIderm GmbH, Hamburg, Germany.
    Background: Palmoplantar psoriasis has significant physical and emotional impact on patients and can be difficult to treat.

    Objective: To evaluate the efficacy of ixekizumab in the treatment of patients with moderate-to-severe plaque psoriasis and moderate-to-severe non-pustular palmoplantar involvement.

    Methods: In three phase 3, double-blind, placebo-controlled trials, patients with moderate-to-severe non-pustular plaque psoriasis [UNCOVER-1 (N = 1296), UNCOVER-2 (N = 1224), UNCOVER-3 (N = 1346)] were randomized to subcutaneous 80 mg ixekizumab every 2 or 4 weeks (Q2W, Q4W), after a 160-mg starting dose, or placebo through week 12. Read More

    1 OF 29